Akari Therapeutics PLC (AKTX)
1.30
+0.06
(+4.84%)
USD |
NASDAQ |
Nov 22, 16:00
1.30
0.00 (0.00%)
After-Hours: 20:00
Akari Therapeutics Cash from Operations (Quarterly): -1.49M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -1.49M |
| June 30, 2024 | -4.894M |
| March 31, 2024 | -4.044M |
| December 31, 2023 | -4.409M |
| September 30, 2023 | -2.449M |
| June 30, 2023 | -4.694M |
| March 31, 2023 | -4.88M |
| June 30, 2022 | -8.574M |
| March 31, 2022 | -5.050M |
| December 31, 2021 | -5.004M |
| September 30, 2021 | -1.559M |
| June 30, 2021 | -4.866M |
| March 31, 2021 | -7.418M |
| December 31, 2020 | -4.233M |
| September 30, 2020 | -0.7042M |
| June 30, 2020 | -4.274M |
| March 31, 2020 | -7.740M |
| December 31, 2019 | -3.464M |
| September 30, 2019 | -4.910M |
| June 30, 2019 | -4.772M |
| March 31, 2019 | 0.2289M |
| Date | Value |
|---|---|
| December 31, 2018 | -4.761M |
| September 30, 2018 | -5.331M |
| June 30, 2018 | -8.284M |
| March 31, 2018 | -4.398M |
| December 31, 2017 | -8.517M |
| September 30, 2017 | -9.214M |
| June 30, 2017 | -4.699M |
| March 31, 2017 | -9.168M |
| December 31, 2016 | -6.494M |
| September 30, 2016 | -4.999M |
| June 30, 2016 | -5.691M |
| March 31, 2016 | -7.441M |
| December 31, 2015 | -6.770M |
| September 30, 2015 | 4.491M |
| June 30, 2015 | -0.6975M |
| March 31, 2015 | -1.988M |
| December 31, 2014 | -0.668M |
| September 30, 2014 | 3.567M |
| June 30, 2014 | -2.328M |
| March 31, 2014 | -2.048M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-8.574M
Minimum
Jun 2022
-0.7042M
Maximum
Sep 2020
-4.430M
Average
-4.552M
Median
Cash from Operations (Quarterly) Benchmarks
| DBV Technologies SA | -22.46M |
| Ascendis Pharma AS | -- |
| Cellectis SA | -5.829M |
| Adaptimmune Therapeutics PLC | -54.45M |
| Biodexa Pharmaceuticals PLC | -- |
Cash from Operations (Quarterly) Related Metrics
| Cash from Financing (Quarterly) | -0.443M |
| Free Cash Flow | -14.84M |
| Free Cash Flow Per Share (Quarterly) | -0.1222 |
| Free Cash Flow Yield | -139.5% |